Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute (TGen), Phoenix, AZ, discusses racial disparities in the treatment of multiple myeloma (MM) in America. He cites systemic issues, delayed diagnoses, and lack of access to therapies as reasons for poorer survival rates among Black American and Hispanic/Latino patients. Efforts like the M-POWER initiative are underway to address these disparities, but Dr Mikhael emphasizes that much work remains to be done. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.